Biopharma · FDA Approvals · Stock

EVO Evotec

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and m…

Assets on file: CELMoD

Catalyst calendar

Dated catalysts for EVO, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for EVO, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 19, 2026
07:06 AM
EVOEvotec

Evotec/BMS: Second CELMoD IND Accepted by FDA

The FDA has accepted the IND for the second molecular glue degrader (CELMoD) candidate discovered under the Evotec-BMS protein degradation partnership. This follows the first candidate entering Phase 1 in March 2026; the second is expected to enter Phase 1 in 2027.

Peers by market cap

Companies in the same sector closest to EVO in market value.